A preclinical study conducted by a group of researchers at the University of Pennsylvania shows promise in treating cystic fibrosis using RNA therapeutics.

Advancements in RNA therapeutic delivery are extending beyond liver-specific treatments, addressing complex challenges and enabling broader applications in medicine. Innovations in lipid nanoparticles, RNA interference, and artificial intelligence are key to this progress, offering potential treatments for a range of diseases and moving closer to personalized medicine. Despite remaining challenges, these developments mark significant strides towards transformative patient care.

From weeks to minutes with Omics Playground

Industry-leading Microfluidizer® processor technology for optimum performance and superior product quality.

Karikó's efforts and dedication have had a profound impact on the world, allowing us to navigate the pandemic with the help of mRNA vaccines.

Product Highlight

From weeks to minutes with Omics Playground

Industry-leading Microfluidizer® processor technology for optimum performance and superior product quality

What needs to be considered for RNA drug delivery? From the stability of LNPs, to proteins in the blood, to descant selection and packaging.

Where is the formulation and delivery of mRNA vaccines heading in the years after the pandemic?

RNA therapeutics have great potential, as evidenced by the success of Pfizer-BioNTech and Moderna’s COVID vaccines. One difficulty that may stunt their success lies in their delivery challenges.

Antonin de Fougerolles explains the development of LNPs which was fundamental in enabling COVID mRNA vaccines. Dr. de Fougerolles also talks on novel delivery methods such as GalNAc conjugates and exosomes.

Despite initial scepticism, RNA therapeutics have proven to be effective for a wide range of diseases and conditions. We are still in a pivotal era of the field, with many new and exciting research projects underway to discover novel applications.

mRNA delivery techniques took a long time to come to fruition, but recent advancements have enabled production at a scale never seen before.

Beyond the blood–brain barrier, the pulmonary power of nebulisers, and RNA science in the post-COVID era

RNA based therapeutics, particularly mRNA, has been experiencing a period of rapid growth, partly due to the influx of funding for mRNA Covid-19 Vaccines. One area that has the potential to benefit from mRNA vaccines is cancer. There are various techniques that have potential to combat the deadly disease.   

This event brought over 600 leading industry minds together to discuss the latest crucial developments in RNA based therapeutics, from mRNA in vaccine development through to microRNA, siRNA, as well as antisense and RNA interference. RNA Therapeutics & Delivery US: Online featured two days of cutting-edge exhibitions and knowledge sharing, consisting of over 30 presentations, roundtables, panel discussions and ask-the-expert Q&As taking place across both days of the event.